NCT03335670Active, not recruitingEarly phase 1
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 14 Jul 2025
Brief summary (registry, in English)
This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study - as such, the images obtained for this study cannot be used clinically or shared with treating oncologists.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 12 Oct 2017
- Start date
- 3 Nov 2017
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Yusuf Menda
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT03335670
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 30
- From 3 Nov 2017 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planned administration of any NET therapy between scan 1 and 2, except for Somatostatin analog.
Other illness
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring hospitalization, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Other
- Physical limitation that would limit compliance with the study requirements
- Pregnant or lactating women. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A negative pregnancy test will be required for all female subjects with child bearing potential.
Who the study is looking for
- Age ≥ 18 years
- Histological diagnosis of neuroendocrine tumor (NET).
- Had a prior 68Ga DOTATATE PET/CT scan (NetSpot) and a CT or MRI with or without contrast performed within 3 months before signing the consent, without interval treatment other than a somatostatin analog.
- CT or MRI must demonstrate at least one lesion (primary or metastatic) present 1.5 cm or larger in any dimension on cross-sectional imaging (CT or MRI) obtained within 3 months of study enrollment.
- Results of CXCR4 immunohistochemistry or slides from biopsy of primary tumor or metastatic lesions available for study analysis.
- Participation in the Iowa Neuroendocrine Tumor Registry.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Holden Comprehensive Cancer Center Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.